Benzoylaconine, found in AC, has been shown to suppress IL-1β-induced expression of IL-6 and IL-8 by inhibiting the activation of MAPKs, Akt, and NF-κB pathways, suggesting its potential as a therapeutic agent for synovial inflammation in RA (Yu et al., 2020). This evidence concerns the gene CXCL8 and rheumatoid arthritis.